



CERTIFICATE OF ANALYSIS No.: 2022-7872





SAMPLE *
CBG CRYSTALLINE POWDER

 Sample condition:
 SUITABLE
 Work order:
 2022-106212
 Sample received:
 21/02/2022

 Sample ID:
 2208020
 Analysis ID:
 2022_042
 Start of analysis:
 21/02/2022

 Sample type:
 Crystal
 Method ID:
 PHL_RPC_12C
 End of analysis:
 22/02/2022

 Method SOP:
 MET-002-03
 Analyst:
 Janez Gerdenc

^{*} Information provided by the client.

CANNABINOID PROFILE	Concentration [% w/w]	Expanded uncertainty [% w/w]	Graphic presentation of relative cannabinoid concentration
CBDV - Cannabidivarin	0.078	0.018	
CBDA - Cannabidiolic acid	< LOQ	n/a	
CBGA - Cannabigerolic acid	< LOQ	n/a	
CBG - Cannabigerol	99.1	6.9	
CBD - Cannabidiol	< LOQ	n/a	
THCV - Tetrahydrocannabivarin	< LOQ	n/a	
CBN - Cannabinol	< LOQ	n/a	
CBC - Cannabichromene	0.060	0.013	
THC - Δ-9-Tetrahydrocannabinol	< LOQ	n/a	
THCA - Δ-9-Tetrahydrocannabinolic acid	< LOQ	n/a	5 5 - 5 - 5 - 65
8-THC - Δ-8-Tetrahydrocannabinol	< LOQ#	n/a	
CBL - Cannabicyclol	< LOQ#	n/a	

Units and abbreviations: % w/w = weight percent, < LOQ = below the limit of quantitation (0.03 % w/w),ND = not detected, n/a = not available.

The results given herein apply only to the sample as received. **Expanded Uncertainty** was calculated using coverage factor k = 2, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:	Approved by:	Authorized by:
	\mathcal{I}	Jan Pate
22/02/2022	Muyn	Jan Jan
	mag. Marko Dragan	dr. Boštjan Jančar
	Analytical Laboratory Manager	Chief Technology Officer
End of Certificate		

PharmaHemp d.o.o. | Cesta v Gorice 8 | 1000 Ljubljana | Slovenia | info@pharma-lab.eu | https://pharma-lab.eu